Emcure Pharmaceuticals Share Price

    NSE
    1279.7
    +9.10 (0.71%)
    EMCURE • 03 Jul, 2025 | 03:29 PM
    BUY
    The current prices are delayed, login or Open Demat Account for live prices.

    Emcure Pharmaceuticals Stock Performance

    1W Return-1.54
    1Y Return0.00
    Today's Low1251.2
    Prev. Close1,270.60
    Mkt Cap (Cr.)24,253.28
    1M Return-4.06
    3Y Return0.00
    52-Week High1580
    Open1,272.10
    PE Ratio76.53
    6M Return-12.64
    Today's High1290
    52-Week Low889
    Face Value10

    Emcure Pharmaceuticals Company background

    Founded in: 1981
    Managing director: SATISH RAMANLAL MEHTA
    Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited, as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay. Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited, through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001.Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broadrange of pharmaceutical products across several major therapeutic areas. They are a research and development driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled to reach target markets across over 70 countries, with a strong presence in India, Europe and Canada. In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, bloodrelated and oncology/antineoplastics. The Company has 13 manufacturing facilities across India. It keeps a strong track record in developing portfolios of differentiated products, including chiral molecules, complex APIs, biologics and novel drug delivery systems. It has a portfolio of 11 chiral molecules, of which 6 have been launched so far.In year 1999, Lasor Drugs Limited was amalgamated with the Company. Thereafter, Emcure Laboratories Private Limited., Lasor Laboratories Limited, Lasor Remedies Limited, Nucron Pharmaceuticals Limited and Hiraral Mehta Sales Private Limited were amalgamated with Company during the period 2001. The Company established facility in Kurkumbh in 2006 and then started operations of injectables facility in Hinjawadi. The facility established by Companys Subsidiary, Gennova Biopharmaceuticals Limited at Hinjawadi became operational.The Company started operations in solid orals at facility in Jammu in 2009. During 2012, it acquired rights of BiCNUr, a branded oncology product prescribed for treatment of brain tumors, multiple myeloma, Hodgkins disease and nonHodgkins lymphoma. Through Subsidiary, Zuventus Healthcare Limited, a manufacturing facility was established in Bengaluru in year 2017 and finally, the Company received licence to work a factory at Sanand, Gujarat in 2018. The subsidiary, Tillomed France S.A.S., was incorporated in France in 2018. The Subsidiary, Emcure Pharma Chile SpA, was incorporated in Chile in 2020. The Company has a portfolio of six commercialized and inhouse manufactured biologics and biologics brands, Elaxim, Tenectase and Hamsyl, each launched into domestic market for the Financial Year 2021. The Company launched biosimilar for Tenecteplase,commonly used for acute myocardial infraction, and the biosimilar for Pegylatedasparaginase, commonly used for treating patients with leukemia. It hold the global patent for use of Tenectaplase to treat Acute Ischemic Stroke as a second indication in 2021 and Emcure Pharma Philippines Inc., incorporated in Philippines in 202122. Tillomed Malta Ltd, was incorporated in Malta in 202223. In July 2024, the Company came up with an Initial Public Offer of issuing 19,375,070 Equity Shares aggregating to Rs 1952.02 Crore comprising a Fresh Issue of 7,946,231 Equity Shares aggregating to Rs 800 Crore and an Offer for Sale of 11,428,839 Equity Shares aggregating to Rs 1152.02 Crore.

    As of 03 Jul, 2025, Emcure Pharmaceuticals share price is ₹1279.8. The stock opened at ₹1272.1 and had closed at ₹1270.6 the previous day. During today’s trading session, Emcure Pharmaceuticals share price moved between ₹1,251.20 and ₹1,290.00, with an average price for the day of ₹1270.60. Over the last 52 weeks, the stock has recorded a low of ₹889.00 and a high of ₹1,580.00. In terms of performance, Emcure Pharmaceuticals share price has declined by 12.6% over the past six months and has declined by 5.84% over the last year.

    Read More
    View details of Market Depth

    Emcure Pharmaceuticals Fundamental

    Market Cap (in crs)

    24,253.28

    Face Value

    10

    Turnover (in lacs)

    2,494.11

    Key Metrics

    Qtr Change %
    43.96% Gain from 52W Low
    23.9
    Dividend yield 1yr %
    0

    Emcure Pharmaceuticals Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Emcure Pharmaceuticals Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    2116.24 Cr
    1962.63 Cr
    2001.98 Cr
    1815.14 Cr
    1771.36 Cr
    Emcure Pharmaceuticals Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022
    7963.26 Cr
    6715.24 Cr
    6031.72 Cr
    5918.86 Cr
    Emcure Pharmaceuticals Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    197.24 Cr
    156.09 Cr
    201.55 Cr
    152.59 Cr
    121.02 Cr
    Emcure Pharmaceuticals Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022
    707.47 Cr
    527.58 Cr
    561.84 Cr
    702.56 Cr

    Emcure Pharmaceuticals Result Highlights

    • Emcure Pharmaceuticals Ltd reported a 9.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a - of -.

    • Its expenses for the quarter were down by 6.9% QoQ and - - YoY.

    • The net profit decreased 22.5% QoQ and - - YoY.

    • The earnings per share (EPS) of Emcure Pharmaceuticals Ltd stood at 6.4 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Emcure Pharmaceuticals

    Promoter
    77.9%
    Foreign Institutions
    3.1%
    Mutual Funds
    2.7%
    Domestic Institutions
    3.4%
    Public
    15.6%
    Promoter
    77.9%
    Foreign Institutions
    3%
    Mutual Funds
    3.1%
    Domestic Institutions
    3.9%
    Public
    15.2%
    Promoter
    78.1%
    Foreign Institutions
    2.9%
    Mutual Funds
    3.3%
    Domestic Institutions
    4%
    Public
    15%

    Emcure Pharmaceuticals Technical Analysis

    Moving Averages Analysis
    1279.7
    Current Price
    Bullish Moving Averages
    7
    Bearish Moving Averages
    9
    5Day EMA
    1,287.50
    10Day EMA
    1,301.10
    12Day EMA
    1,303.90
    20Day EMA
    1,302.10
    26Day EMA
    1,291.90
    50Day EMA
    1,242.90
    100Day EMA
    1,208.40
    200Day EMA
    1,268.30
    5Day SMA
    1,285.10
    10Day SMA
    1,308.40
    20Day SMA
    1,325.30
    30Day SMA
    1,330.60
    50Day SMA
    1,216.90
    100Day SMA
    1,116.30
    150Day SMA
    1,198.60
    200Day SMA
    1,254.90
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    135913 Rs
    202851 Rs
    Week Rs
    117722 Rs
    169548 Rs
    Month Rs
    135239 Rs
    194079 Rs
    1,273.67
    Pivot
    Resistance
    First Resistance
    1,296.13
    Second Resistance
    1,312.47
    Third Resistance
    1,334.93
    Support
    First Support
    1,257.33
    Second support
    1,234.87
    Third Support
    1,218.53
    Relative Strength Index
    47.64
    Money Flow Index
    35.47
    MACD
    12.05
    MACD Signal
    28.46
    Average True Range
    45.06
    Average Directional Index
    32.63
    Rate of Change (21)
    -4.06
    Rate of Change (125)
    -12.36

    Emcure Pharmaceuticals Latest News

    03 JUL 2025 | Thursday

    Emcure Pharma Block Deal: Public Shareholder BC Investments To Sell 2.4% Stake

    25 JUN 2025 | Wednesday

    Emcure Pharmaceuticals Ltd - 544210 - Closure of Trading Window

    25 JUN 2025 | Wednesday

    Emcure Pharmaceuticals Ltd - 544210 - Intimation Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Submission Of Application For Seeking Re-Classification From The 'Promoter And Promoter Group' Category To 'Public' Category

    View More

    Emcure Pharmaceuticals Share Price FAQs

    Emcure Pharmaceuticals share price is ₹1279.7 in NSE and ₹1281.15 in BSE as on 3/7/2025.

    Emcure Pharmaceuticals share price in the past 1-year return was 0. The Emcure Pharmaceuticals share hit a 1-year low of Rs. 889 and a 1-year high of Rs. 1580.

    The market cap of Emcure Pharmaceuticals is Rs. 24253.28 Cr. as of 3/7/2025.

    The PE ratios of Emcure Pharmaceuticals is 76.53 as of 3/7/2025.

    The PB ratios of Emcure Pharmaceuticals is 8.02 as of 3/7/2025

    The Mutual Fund Shareholding in Emcure Pharmaceuticals was 2.73% at the end of 3/7/2025.

    You can easily buy Emcure Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Emcure Pharmaceuticals share price is ₹1580 and ₹889 as of 3/7/2025.

    Please be aware that Emcure Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.27
    +0.48 (+0.74%)
    139.70
    -0.61 (-0.43%)
    690.40
    +1.85 (+0.27%)
    2,611.20
    -19.00 (-0.72%)
    167.52
    -0.71 (-0.42%)
    390.65
    -2.00 (-0.51%)
    165.91
    +0.03 (+0.02%)
    260.85
    +1.10 (+0.42%)
    426.25
    -0.70 (-0.16%)
    399.90
    -6.75 (-1.66%)
    Top Gainers
    7,565.00
    +124.00 (+1.67%)
    1,291.30
    +20.50 (+1.61%)
    4,310.60
    +66.90 (+1.58%)
    244.05
    +2.98 (+1.24%)
    12,752.00
    +130.00 (+1.03%)
    Top Losers
    1,810.20
    -46.60 (-2.51%)
    2,126.60
    -42.50 (-1.96%)
    910.15
    -12.85 (-1.39%)
    1,980.70
    -27.20 (-1.35%)
    1,046.10
    -13.80 (-1.30%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -